Ponesimod: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01523-z
Abstract: Ponesimod (PONVORY™) is an orally administered selective sphingosine-1-phosphate (S1P) receptor 1 (S1P1) agonist being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson for the treatment of multiple sclerosis (MS). Based on the results… read more here.
Keywords: first approval; ponesimod; ponesimod first;